US 9725470
Substituted naphthyridines as JAK kinase inhibitors
granted A61KA61K31/46A61K45/06
Quick answer
US patent 9725470 (Substituted naphthyridines as JAK kinase inhibitors) held by Theravance Biopharma R&D IP, LLC expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/46, A61K45/06, A61P, A61P1/00